Page 25 - ITPS-6-1

19 INNOSC Theranostics and Pharmacological Sciences, 2023, Vol. 6, No. 1
patients. The failure of chemosurveillance is
a result of cancer treatments that focus on cell
death, such as cytotoxic drugs, radiotherapy, and
immunotherapy. To prevent the development of
pulmonary fibrosis following COVID-19 infection,
cancer patients are recommended to switch their
medications to targeted therapies entailing DIs or
DHIs that promote wound healing.
To end the threat posed by the COVID-19
pandemic, new treatments for pulmonary fibrosis
must be developed. COVID-19 symptoms are
varied from minor upper respiratory tract symptoms
to serious acute respiratory distress syndrome.
The main risk factors for serious COVID-19 are
similar to those for idiopathic pulmonary fibrosis,
including aging and having comorbid conditions
such as diabetes and hypertension. Moreover,
due to their immunosuppressed state brought due
to their disease and anticancer therapies such as
chemotherapy, cancer patients are more vulnerable
to serious COVID-19 complications.
Acknowledgments
None.
Funding
None.
Conflict of interest
The author declares no conflicts of interests.
Author contributions
This is single-authored manuscript.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Availability of data
Not applicable.
References
[1] Yang, L.; Liu, S.; Liu, J.; Zhang, Z.; Wan, X.; Huang, B.;
Chen, Y.; Zhang, Y. COVID-19: Immunopathogenesis
and Immunotherapeutics. Signal Transduct. Target Ther.,
©2023 AccScience Publishing
Dudhat
2020, 5(1), 128.
[2] Ciotti, M.; Ciccozzi, M.; Terrinoni, A.; Jiang, W.C.; Wang, C.B.;
Bernardini, S. The COVID-19 Pandemic. Crit. Rev. Clin. Lab. Sci.,
2020, 57(6), 365–88.
[3] Le, T.T.; Andreadakis, Z.; Kumar, A.; Román, R.G.; Tollefsen, S.;
Saville, M.; Mayhew, S. The COVID-19 Vaccine Development
Landscape. Nat. Rev. Drug Discov., 2020, 19(5), 305–6.
[4] Fauci, A.S.; Lane, H.C.; Redfield, R.R. Covid-19-Navigating the
[5] Uncharted. N. Engl. J. Med., 2020, 382, 1268–9.
Daniel, S.J. Education and the COVID-19 Pandemic. Prospects
(Paris), 2020, 49(1), 91–6.
[6] Le, T.T.; Andreadakis, Z.; Kumar, A.; Román, R.G.; Tollefsen, S.;
Saville, M.; Mayhew, S. The COVID-19 Vaccine Development
Landscape. Nat. Rev. Drug Discov., 2020, 19(5), 305–6.
[7] Velavan, T.P.; Meyer, C.G. The COVID-19 Epidemic. Trop. Med.
[8] Int. Health, 2020, 25(3), 278–80.
Yuki, K.; Fujiogi, M.; Koutsogiannaki, S.J. COVID-19
Pathophysiology: A Review. Clin. Immunol., 2020, 215, 108427.
[9] Iba, T.; Levy, J.H.; Connors, J.M.; Warkentin, T.E.; Thachil, J.;
Levi, M. The Unique Characteristics of COVID-19 Coagulopathy.
Crit. Care, 2020, 24(1), 360.
[10] Cao, X. COVID-19: Immunopathology and its Implications for
[11] Therapy. Nat. Rev. Immunol., 2020, 20(5), 269–70.
Zhang, L.; Zhu, F.; Xie, L.; Wang, C.; Wang, J.; Chen, R.;
Jia, P.; Guan, H.Q.; Peng, L.; Chen, Y.; Peng, P.; Zhang, P.;
Chu, Q.; Shen, Q.; Wang, Y.; Xu, S.Y.; Zhao, J.P.; Zhou, M.
Clinical Characteristics of COVID-19-Infected Cancer Patients:
A Retrospective Case Study in Three Hospitals Within Wuhan,
China. Ann. Oncol., 2020, 31(7), 894–901.
[12] Luo, J.; Rizvi, H.; Preeshagul, I.R.; Egger, J.V.; Hoyos, D.;
Bandlamudi, C.; McCarthy, C.G.; Falcon, C.J.; Schoenfeld, A.J.;
Arbour, K.C.; Chaft, J.E.; Daly, R.M.; Drilon, A.; Eng, J.; Iqbal, A.;
Lai, W.V.; Li, B.T.; Lito, P.; Namakydoust, A.; Ng, K.; Offin, M.;
Paik, P.K.; Riely, G.J.; Rudin, C.M.; Yu, H.A.; Zauderer, M.G.;
Donoghue, M.T.A.; Łuksza, M.; Greenbaum, B.D.; Kris, M.G.;
Hellmann, M.D. COVID-19 in Patients with Lung Cancer. Ann.
Oncol., 2020, 31(10), 1386–96.
[13] Pinato, D.J.; Patel, M.; Scotti, L.; Colomba, E.; Dolly, S.;
Loizidou, A.; Chester, J.; Mukherjee, U.; Zambelli, A.;
Pria, A.D.; Aguilar-Company, J.; Bower, M.; Salazar, R.;
Bertuzzi, A.; Brunet, J.; Lambertini, M.; Tagliamento, M.;
Pous, A.; Sita-Lumsden, A.; Srikandarajah, K.; Colomba, J.;
Pommeret, F.; Seguí, E.; Generali, D.; Grisanti, S.; Pedrazzoli, P.;
Rizzo, G.; Libertini, M.; Moss, C.; Evans, J.S.; Russell, B.;
Harbeck, N.; Vincenzi, B.; Biello, F.; Bertulli, R.; Ottaviani, D.;
Liñan, R.; Rossi, S.; Carmona-García, M.C.; Tondini, C.;
Fox, L.; Baggi, A.; Fotia, V.; Parisi, A.; Porzio, G.; Queirolo, P.;
Cruz, C.A.; Saoudi-Gonzalez, N.; Felip, E.; Lloveras, A.R.;
Newsom-Davis, T.; Sharkey, R.; Roldán, E.; Reyes, R.; Zoratto, F.;
Earnshaw, I.; Ferrante, D.; Marco-Hernández, J.; Ruiz-Camps, I.;
Gaidano, G.; Patriarca, A.; Bruna, R.; Sureda, A.; Martinez-Vila, C.;
de Torre, A.S.; Berardi, R.; Giusti, R.; Mazzoni, F.; Guida, A.;
Rimassa, L.; Chiudinelli, L.; Franchi, M.; Krengli, M.; Santoro, A.;
Prat, A.; Tabernero, J.; Van Hemelrijck, M.; Diamantis, N.;
Gennari, A.; Cortellini, A. Time-Dependent COVID-19 Mortality
in Patients with Cancer: An Updated Analysis of the OnCovid
Registry. JAMA Oncol., 2022, 8(1), 114–22.
[14] Robinson, A.G.; Gyawali, B.; Evans, G. COVID-19 and Cancer:
Do We Really Know What We Think We Know? Nat. Rev. Clin.
Oncol., 2020, 17(7), 386–8.
[15] Jee, J.; Foote, M.B.; Lumish, M.; Stonestrom, A.J.; Wills, B.;
Narendra, V.; Avutu, V.; Murciano-Goroff, Y.R.; Chan, J.E.;
Derkach, A.; Philip, J.; Belenkaya, R.; Kerpelev, M.; Maloy, M.;
Watson, A.; Fong, C.; Janjigian, Y.; Diaz, L.A. Jr.; Bolton, K.L.;
Pessin, M.S. Chemotherapy and COVID-19 Outcomes in Patients
with Cancer. J. Clin. Oncol., 2020, 38(30), 3538–46.
[16] Al-Quteimat, O.M.; Amer, A.M. The Impact of the COVID-19
Pandemic on Cancer Patients. Am. J. Clin. Oncol., 2020, 43, 452–5.
[17] Grivas, P.; Khaki, A.; Wise-Draper, T.; French, B.; Hennessy, C.;